AMT-253 treatment for advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a non-randomized, open-label, multicenter Phase I/II study evaluating the safety and efficacy of AMT-253 in patients with unresectable or metastatic malignant melanoma and other advanced solid tumors. The study consists of a Phase I dose escalation to determine the optimal dosing and a Phase II dose expansion to further assess the treatment's effectiveness. Participants must have experienced disease progression after at least one prior systemic therapy and have no available standard treatment options.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Patients must be willing and able to understand and sign the ICF, and to adhere to the study visit schedule and other protocol requirements.
* 2\. Patients with histologically confirmed melanoma or other advanced solid tumor.
* 3\. Patients who have undergone at least one systemic therapy and have radiologically or clinically determined progressive disease (PD) during or after most recent line of therapy, and for whom no further standard therapy is available, or who are intolerable to standard therapy.
* 4\. Patients must have at least one measurable lesion as per RECIST version 1.1.
* 5\. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
* 6\. Life expectancy ≥ 3 months.
* 7\. Patients must have adequate organ function
* 8\. Women of child bearing potential (WCBP), defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally postmenopausal for at least 12 consecutive months must agree to use two effective contraceptive methods while on study treatment and for at least twelve weeks after the last dose of the IMP.
* 9\. WCBP must have a negative serum pregnancy test within 7 days prior to first dose of the IMP.
* 10\. Male patients must agree to use a latex condom, even if they had a successful vasectomy, while on study treatment and for at least twelve weeks after the last dose of the IMP.
* 11\. Male patients must agree not to donate sperm, and female patients must agree not to donate eggs, while on study treatment and for at least 12 weeks after the last dose of the IMP.
* 12\. Availability of tumor tissue sample at screening.

Exclusion Criteria:

* 1\. Prior treatment with any agent that has the same target.
* 2\. Central nervous system (CNS) metastasis.
* 3\. Active or chronic skin disorder requiring systemic therapy.
* 4\. History of Steven's Johnson's syndrome or toxic epidermal necrolysis syndrome.
* 5\. Persistent toxicities from previous systemic anti-neoplastic treatments of Grade \>1.
* 6\. Systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the IMP.
* 7\. Major surgery within 28 days prior to first dose of the IMP, or no recovery from side effects of such intervention.
* 8\. Significant cardiac disease, such as recent myocardial infarction or acute coronary syndromes, congestive heart failure， uncontrolled hypertension, uncontrolled cardiac arrhythmias.
* 9\. History of thromboembolic or cerebrovascular events, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis, or pulmonary emboli within six months prior to first dose of the IMP.
* 10\. Acute and/or clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV).
* 11\. Administration of a live vaccine within 28 days prior to the administration of the first dose of the IMP.

Where it's running

• Beijing Cancer Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Minqi Guan
• Email: minqi.guan@multitudetherapeutics.com
• Phone: 86-15895820062

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• AK157D1 injection for advanced solid tumors

  A first-in-human Phase 1 study tests AK157D1 injection in adults with unresectable advanced solid tumors to see if it is safe and tolerable and to get early signs of how it behaves in the body and against tumors.

  Recruiting Phase 1 Akeso · Harbin, Heilongjiang and 2 other locations · NCT07847281

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• MK-2010 alone or with other treatments for advanced solid tumors

  This trial tests MK-2010, by itself or with other cancer medicines, to see if it helps people with advanced solid tumors.

  Recruiting at 7 sites Phase 2 Merck Sharp & Dohme LLC · Belleville, New Jersey and 6 other locations · NCT07793942

• Whole-Body Infrared Heating for Advanced Solid Tumors

  This study looks at how ET-SPACE whole-body infrared hyperthermia affects people with advanced solid tumors to see if it changes biology, symptoms, and safety.

  Recruiting Zhejiang Hospital · Hangzhou, Zhejiang · NCT07793214

• Social prescriptions and micro-learning to improve cancer care

  This study tests a multicomponent program using social prescriptions and short online learning to help cancer patients and their chosen support persons in Germany.

  Recruiting University of Regensburg · Augsburg, Bavaria and 7 other locations · NCT07788729

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.